Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review

被引:0
作者
Saeed Sheikh Gholami
Farbod Ebadi Fard Azar
Aziz Rezapour
Masih Tajdini
机构
[1] Iran University of Medical Sciences,Department of Health Economics, School of Health Management and Information Sciences
[2] Iran University of Medical Sciences,Health Management and Economics Research Center
[3] Tehran University of Medical Sciences,Tehran Heart Center
来源
Heart Failure Reviews | 2019年 / 24卷
关键词
Cost-effectiveness; Coronary artery disease; Coronary artery bypass graft; Percutaneous coronary intervention; Medical therapy; Economic evaluation;
D O I
暂无
中图分类号
学科分类号
摘要
Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.
引用
收藏
页码:967 / 975
页数:8
相关论文
共 190 条
[1]  
Hlatky MA(2009)Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials Lancet 373 1190-1197
[2]  
Boothroyd DB(2007)A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease Circulation 115 1082-1089
[3]  
Bravata DM(1994)Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial Lancet 344 927-930
[4]  
Boersma E(2001)Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease N Engl J Med 344 1117-1124
[5]  
Booth J(2018)Effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy: a systematic review protocol Medicine. 97 e9958-1078
[6]  
Brooks MM(1990)Coronary artery surgery study (CASS): comparability of 10 year survival in randomized and randomizable patients J Am Coll Cardiol 16 1071-752
[7]  
Carrié D(2000)Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty Versus Surgery Trial (EAST) Am J Cardiol 86 747-20
[8]  
Clayton TC(2008)Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients clinical perspective Circulation: Cardiovascular Quality and Outcomes 1 12-SS50
[9]  
Danchin N(2012)Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial Circulation 126 S145-69
[10]  
Flather M(2014)Factors affecting the technical efficiency of health systems: a case study of Economic Cooperation Organization (ECO) countries (2004–10) Int J Health Policy Manag 3 63-700